A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

Clinical trial NCT00818662 · COMPLETED

Trial details

NCT number: NCT00818662
Sponsor: Baxalta now part of Shire
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Alzheimer´s Disease

Start date: 2008-12-19
Primary completion: 2012-12-10
Enrollment: 390

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.